FDA Authorizes the First Nicotine Pouches (2025)

On Thursday 16 January 2025 the U.S. Food and Drug Administration issued marketing orders for 20 nicotine pouch products made by one manufacturer — ten flavours, each in a 3 milligram and a 6 milligram strength. According to the agency’s news release, it was “the first time the agency has authorized products commonly referred to as nicotine pouches.” The orders allow those specific products to be sold legally in the United States to adults 21 and older; the release states that this “does not mean these tobacco products are safe, nor are they ‘FDA approved.’” The substance itself — its pharmacology, toxicity and the published research — is described on the site’s Nicotine pages.

Table of Contents

  1. What the FDA Did
  2. What a Nicotine Pouch Is and Which Products Were Covered
  3. The Legal Standard: The Premarket Tobacco Pathway
  4. The Evidence the FDA Cited
  5. The Youth-Use Data in the Decision
  6. Marketing Restrictions and Conditions
  7. What the Authorization Does Not Do
  8. The Other Nicotine Pouch Steps of 2025
  9. Later Status: The 2026 Modified-Risk Orders
  10. Dates and Legal Status as of October 11, 2026
  11. How the Orders Fit the FDA’s Earlier Tobacco Actions
  12. Primary Documents
  13. Key Research Papers
  14. Connections

1. What the FDA Did

The FDA news release dated 16 January 2025 — titled “FDA Authorizes Marketing of 20 … Nicotine Pouch Products after Extensive Scientific Review,” with the subheading “Agency Will Closely Monitor Youth Use and Company’s Compliance with Marketing Restrictions” — states that the agency “authorized the marketing of 20 … nicotine pouch products through the premarket tobacco product application (PMTA) pathway following an extensive scientific review.”

The legal instrument is called a marketing granted order. It is a decision on one manufacturer’s applications for specific products, not a rule that applies to a whole category of products, and it was announced through an FDA news release rather than a rule in the Federal Register. The release was issued from the FDA newsroom and is listed on the Center for Tobacco Products (CTP) page “2025 News and Events” under January 2025.

The FDA attributes the decision to its Center for Tobacco Products, the part of the agency that has regulated tobacco products since the 2009 Family Smoking Prevention and Tobacco Control Act. The release quotes two officials then in office: Matthew Farrelly, Ph.D., director of the Office of Science in the Center for Tobacco Products, and Brian King, Ph.D., M.P.H., director of the Center for Tobacco Products.

Back to Table of Contents

2. What a Nicotine Pouch Is and Which Products Were Covered

The release describes nicotine pouches as “small synthetic fiber pouches containing nicotine designed to be placed between a person’s gum and lip.”

The 20 authorized products are ten flavours of one manufacturer’s pouch line, each in two nicotine strengths, 3 milligrams and 6 milligrams per pouch. The flavours named in the order are chill, cinnamon, citrus, coffee, cool mint, menthol, peppermint, smooth, spearmint and wintergreen. The release states that the authorizations are “specific to these products only” and do not apply to any other nicotine pouch or to the manufacturer’s other products.

Back to Table of Contents

Under the 2009 Tobacco Control Act, new tobacco products need an FDA marketing authorization before they can be sold in the United States. The route used here is the premarket tobacco product application, or PMTA: the manufacturer submits its evidence and the FDA reviews it against the law’s public health standard. The release calls this the agency’s effort “to ensure all new tobacco products marketed in the U.S. undergo science-based review.”

The release explains that this standard “considers the risks and benefits of products to the population as a whole” — not only to the person using the product. In practice the FDA weighs the possible benefit to adults who switch from cigarettes or other smokeless tobacco to a lower-risk product against the possible harm to young people and non-users who might start using it. The release states that the FDA determined these specific products “met the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act.”

A PMTA order is separate from a modified risk tobacco product (MRTP) order, a second and optional authorization that a manufacturer needs before it may tell consumers that a product carries a lower risk of disease (see section 9).

Back to Table of Contents

4. The Evidence the FDA Cited

The release lists the main findings behind the orders:

The Office of Science director is quoted: “To receive marketing authorizations, the FDA must have sufficient evidence that the new products offer greater benefits to population health than risks. In this case, the data show that these nicotine pouch products meet that bar by benefiting adults who use cigarettes and/or smokeless tobacco products and completely switch to these products.”

Back to Table of Contents

5. The Youth-Use Data in the Decision

Because the legal standard counts the risk to young people, the release reports that the FDA “reviewed data regarding youth risk and found that youth use of nicotine pouches remains low despite growing sales in recent years.” The figure it gives comes from the 2024 National Youth Tobacco Survey, a yearly federal survey of U.S. middle and high school students: 1.8% reported currently using nicotine pouches.

The director of the Center for Tobacco Products is quoted: “It’s critical that the manufacturer market these products responsibly to prevent youth use. While current data show that youth use remains low, the FDA is closely monitoring the marketplace and is committed to taking action, as appropriate, to best protect public health.”

Published research since the decision has continued to track youth use; several of the papers in the Key Research Papers list below report national survey and cohort data on adolescents and young adults.

Back to Table of Contents

6. Marketing Restrictions and Conditions

The release states that the authorizations “impose stringent marketing restrictions for digital, TV and radio, including measures to ensure ads are carefully targeted to adults ages 21 and older and the demographics of the audiences reached by the ads are tracked and measured by the manufacturer.”

It also reports measures the company itself stated it intends to take: no mass-market advertising on radio and television; marketing actors and models no younger than 35 and not styled to look younger; and no content designed to appeal to young people, including characters, images or themes. These are described as the company’s stated intentions alongside the order’s own restrictions.

The orders can be taken back. In the release’s words, the agency “may suspend or withdraw a marketing granted order issued under the PMTA pathway for a variety of reasons if the agency determines the continued marketing of a product no longer meets the necessary public health standard, such as if there is a notable increase in youth initiation.”

Back to Table of Contents

7. What the Authorization Does Not Do

Back to Table of Contents

8. The Other Nicotine Pouch Steps of 2025

The CTP “2025 News and Events” list shows that the January orders were followed by several more pouch-related actions during the year:

Back to Table of Contents

9. Later Status: The 2026 Modified-Risk Orders

On 30 June 2026 the FDA issued modified risk granted orders for the same 20 products. According to the CTP announcement, the products may now be marketed with a claim that using them instead of cigarettes “puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” That sentence is the wording the FDA authorized the manufacturer to use; it is reported here as the agency’s decision, not as a view of this site.

The announcement states that the FDA concluded the manufacturer had shown the claim to be scientifically accurate for these products, that consumers understand it, and that marketing the products with it would benefit the population as a whole. It lists what the agency considered: the 22 January 2026 advisory committee meeting, public comments, the applications, and other scientific information. It also notes that a modified risk order “refers to specific products, not an entire class of tobacco products.”

The orders expire after five years unless renewed, require the manufacturer to run postmarket surveillance and studies of users’ behaviour and understanding of the claim, and may be withdrawn “if there is a significant increase in youth uptake.” The same announcement states that “fully quitting the use of all forms of tobacco products would most benefit” the health of adults who smoke. An FDA update dated 4 August 2026 reports that, after four further authorizations under the pilot program, the agency had authorized 30 nicotine pouches in total.

Back to Table of Contents

10. Dates and Legal Status as of October 11, 2026

No 2026 follow-up page on this site covers these orders yet; the 2026 FDA actions the site reports are listed on the FDA and Regulation hub.

Back to Table of Contents

11. How the Orders Fit the FDA’s Earlier Tobacco Actions

The release places the orders among “many the FDA has taken to ensure all new tobacco products marketed in the U.S. undergo science-based review.” It reports that the FDA had by then received applications for nearly 27 million products and made determinations on more than 26 million of them. It also lists earlier authorizations of flavoured oral tobacco products: nicotine mints and chews in 2021 and a mint smokeless tobacco product in 2015.

The same month, the CTP list shows, the FDA also proposed reducing nicotine in cigarettes and certain other combusted tobacco products to a minimally addictive or nonaddictive level; that proposal and the withdrawal of the menthol and flavoured-cigar rules are covered on the site’s page Menthol, Flavored Cigar and Nicotine Cap Rules Withdrawn (2025). Together the two pages show the two directions of the agency’s tobacco work in early 2025: authorizing specific non-combusted products for adults while proposing limits on cigarettes.

The release points readers to the FDA’s online tobacco products database on fda.gov for the full list of tobacco products that may legally be sold, and the agency’s list of authorized nicotine pouches is at the address given under Primary Documents.

Back to Table of Contents

12. Primary Documents

  1. U.S. Food and Drug Administration (2025). FDA Authorizes Marketing of 20 … Nicotine Pouch Products after Extensive Scientific Review. FDA News Release, 16 January 2025 — FDA news release, 16 January 2025
  2. FDA Center for Tobacco Products. 2025 News and Events (content current as of 26 May 2026) — fda.gov, CTP 2025 News and Events
  3. FDA Center for Tobacco Products (2025). Modified Risk Applications for … Nicotine Pouches Now Under FDA Scientific Review. CTP Newsroom, 17 June 2025. Docket No. FDA-2025-N-0835 — CTP newsroom, 17 June 2025
  4. U.S. Food and Drug Administration (2025). FDA Urges Nicotine Pouch Manufacturers To Use Child-Resistant Packaging Following Increasing Reports of Accidental Exposure. FDA News Release, 2 September 2025 — FDA news release, 2 September 2025
  5. FDA Center for Tobacco Products (2025). FDA Launches Program to More Efficiently Review Nicotine Pouch Applications. CTP Newsroom, 18 September 2025 — CTP newsroom, 18 September 2025
  6. Food and Drug Administration, HHS (2025). Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Federal Register 90:52969–52971, 24 November 2025. Docket No. FDA-2025-N-0835 — FR Doc. 2025-20768 (official PDF, govinfo.gov)
  7. FDA Center for Tobacco Products (2025). FDA Authorizes 6 Nicotine Pouch Products, Completing Review in Record Time. CTP Newsroom, December 2025 — CTP newsroom, December 2025
  8. FDA Center for Tobacco Products (2026). FDA Authorizes 20 … Nicotine Pouches to Be Marketed with Specific Modified Risk Claim. CTP Newsroom, 30 June 2026 — CTP newsroom, 30 June 2026
  9. FDA Center for Tobacco Products (2026). Pilot Program Update: FDA Authorizes 4 New Nicotine Pouches. CTP Newsroom, 4 August 2026 — CTP newsroom, 4 August 2026
  10. FDA list of authorized nicotine pouch products — fda.gov/authorizednicotinepouches

The ellipses in the document titles above stand in for the manufacturer’s brand name, which this site does not print.

Back to Table of Contents

Key Research Papers

  1. Azzopardi D, Liu C, Murphy J (2022). Chemical characterization of tobacco-free “modern” oral nicotine pouches and their position on the toxicant and risk continuums. Drug and Chemical Toxicology 45(5):2246-2254 — PubMed PMID: 34034614
  2. Scherer G, Pluym N, Scherer M (2024). Oral health risks in adults who use electronic nicotine delivery systems and oral nicotine pouches: a critical review of the literature and qualitative synthesis of the available evidence. Harm Reduction Journal 21(1):229 — PubMed PMID: 39736680
  3. Hartmann-Boyce J, Tattan-Birch H, Brown J, Shahab L, Goniewicz ML, Ma CL, Wu AD, Travis N, Jarman H, Livingstone-Banks J, Lindson N (2025). Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products. Cochrane Database of Systematic Reviews 10:CD016220 — PubMed PMID: 41130602
  4. Heshmati J, Bates EL, Shahen S, Visintini S, Quirouette E, Mullen KA, Mir H (2025). Nicotine pouch pharmacokinetics compared to smoked tobacco: a systematic review and meta-analysis. Drug and Alcohol Dependence Reports 17:100389 — PubMed PMID: 41246258
  5. Olivas M, Hays HL, Kistamgari S, Rine NI, Zhu M, Yang J, Smith GA (2025). Nicotine ingestions among young children: 2010-2023. Pediatrics 156(2) — PubMed PMID: 40658193
  6. Felicione NJ, Ozga JE, Eversole A, Hart JL, Tackett A, Hrywna M, Halquist M, Stanton CA (2026). Oral nicotine pouches: rising popularity and state of the science. Public Health Reports 141(1):55-62 — PubMed PMID: 40293136
  7. Kreslake JM, Azadi M, Iskra ML, Schillo BA (2026). Oral nicotine pouch initiation and characteristics of use among US adolescents and young adults, 2022-2024. American Journal of Public Health (published online 6 August 2026):e1-e4 — PubMed PMID: 42561179
  8. Seaman Jones EL, Cordova J, Hoffmeyer N, Pacek LR, Delnevo CD, Tynan MA, Marynak K (2026). E-cigarette and nicotine pouch use among youth, United States, 2025. NEJM Evidence EVIDpha2600171 — PubMed PMID: 42832284

PubMed Topic Searches

  1. PubMed: oral nicotine pouches
  2. PubMed: nicotine pouches and youth use
  3. PubMed: nicotine pouch pharmacokinetics
  4. PubMed: nicotine pouch exposures in children

Back to Table of Contents

Connections

Back to Table of Contents